Global Fibromyalgia Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Diagnosis;
Blood Tests and Others.By Treatment;
Medication, Therapy, and Others.By Route of Administration;
Oral, Parenteral, and Others.By End User;
Hospitals, Homecare, Specialty Clinics, and Others.By Distribution Channel;
Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Fibromyalgia Market (USD Million), 2021 - 2031
In the year 2024, the Global Fibromyalgia Market was valued at USD 2,543.12 million. The size of this market is expected to increase to USD 4,401.01 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.2%.
The global fibromyalgia market is poised for significant growth in the foreseeable future, driven by factors such as emerging markets and substantial investments in research and development. The market is bolstered by the increasing prevalence of fibromyalgia cases worldwide and the heightened focus on research initiatives conducted by pharmaceutical companies. According to the European Network of Fibromyalgia Associations (ENFA), millions of individuals across Europe and globally are affected by fibromyalgia. Additionally, the COVID-19 pandemic has also played a significant role in shaping market dynamics.
Data Bridge Market Research anticipates a steady growth rate for the global fibromyalgia market over the forecast period. The expected compound annual growth rate (CAGR) is projected to be around 7%. The market, valued at a significant figure is expected to witness substantial expansion by the end of the forecast period. The market report compiled by the Data Bridge Market Research team offers valuable insights into various aspects such as market value, growth rate, market segments, geographical coverage, key market players, and the overall market scenario. Additionally, the report provides in-depth expert analysis, patient epidemiology, pipeline analysis, pricing trends, and regulatory framework.
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain, accompanied by symptoms such as sleep disturbances, memory issues, fatigue, and mood disturbances. It is believed that fibromyalgia disrupts the brain's processing of pain signals, although the exact cause remains unclear. Factors such as genetic predisposition, chronic infections, and physical or emotional trauma are believed to contribute to the development of fibromyalgia. Females are at a higher risk of developing fibromyalgia compared to males, and conditions such as rheumatoid arthritis, osteoarthritis, or lupus may also be associated with fibromyalgia.
Global Fibromyalgia Market Recent Developments
-
In January 2023, Amneal Pharmaceuticals, Inc. signed a long-term license agreement with Orion Corporation to commercialize several Amneal’s complex generic products to market in Europe, Australia, and New Zealand.
-
In May 2020, AbbVie completed its acquisition of Allergan Plc following receipt of regulatory approval from all government authorities required by the transaction agreement.
Segment Analysis
The Global Fibromyalgia Market can be segmented across several dimensions to provide a comprehensive analysis of the market landscape. Firstly, by diagnosis, the market includes blood tests for biomarkers associated with fibromyalgia, as well as other diagnostic modalities such as imaging tests and clinical assessments. Regarding treatment options, the market encompasses medications targeting pain relief and symptom management, various forms of therapy including physical therapy, cognitive-behavioral therapy, and complementary and alternative medicine approaches, as well as other emerging treatments such as neuromodulation therapies. Additionally, the route of administration for fibromyalgia treatments includes oral medications, parenteral injections, and other delivery methods such as transdermal patches or topical formulations. Furthermore, the end users of fibromyalgia treatments span hospitals, where patients may receive acute care or specialized interventions, homecare settings for long-term management, specialty clinics offering multidisciplinary care, and other healthcare facilities. Lastly, distribution channels for fibromyalgia medications include hospital pharmacies within healthcare institutions, online pharmacies for convenient access, and retail pharmacies serving community-based patients. This segmentation provides valuable insights into the diverse aspects of the Global Fibromyalgia Market, facilitating targeted interventions and tailored approaches to address the complex needs of patients and healthcare providers.
Global Fibromyalgia Segment Analysis
In this report, the Global Fibromyalgia Market has been segmented by Diagnosis, Treatment, Route of Administration, End User, Distribution Channel, and Geography.
Global Fibromyalgia Market, Segmentation by Diagnosis
The Global Fibromyalgia Market has been segmented by Diagnosis into Blood Tests and Others.
Although there is no specific blood test to definitively diagnose fibromyalgia, several biomarkers have been studied for their potential utility in aiding diagnosis and guiding treatment decisions. These biomarkers may include markers of inflammation, immune dysregulation, neuroendocrine dysfunction, and oxidative stress, which are believed to play a role in the pathogenesis of fibromyalgia. Blood tests such as complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and markers of neurotransmitter levels (e.g., serotonin, dopamine) may be employed to assess inflammatory markers, immune system activity, and neurochemical imbalances associated with fibromyalgia. Additionally, genetic testing and gene expression profiling have emerged as promising diagnostic tools for identifying genetic predispositions and molecular signatures associated with fibromyalgia susceptibility and severity. While blood tests provide valuable insights into the physiological and molecular mechanisms underlying fibromyalgia, they are often used in conjunction with clinical assessment and symptom evaluation to establish a comprehensive diagnosis and develop personalized treatment plans. Apart from blood tests, other diagnostic approaches for fibromyalgia may include clinical evaluation, physical examination, symptom assessment tools (e.g., Fibromyalgia Impact Questionnaire), and imaging studies (e.g., magnetic resonance imaging, positron emission tomography). Overall, the segmentation of the Global Fibromyalgia Market by Diagnosis into Blood Tests and Others reflects the diverse array of diagnostic modalities available for identifying and characterizing fibromyalgia, highlighting the importance of a multidimensional approach to diagnosis and management in addressing the complex nature of this debilitating condition.
Global Fibromyalgia Market, Segmentation by Treatment
The Global Fibromyalgia Market has been segmented by Treatment into Medication, Therapy, and Others.
The market is segmented into Medication, encompassing pharmacological interventions aimed at alleviating pain, improving sleep quality, and managing associated symptoms. Medications commonly prescribed for fibromyalgia include analgesics, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, which help mitigate pain and inflammation. Additionally, antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), are often prescribed to manage mood disturbances and enhance sleep. Furthermore, anticonvulsants, muscle relaxants, and sleep aids may be utilized to address specific symptoms and improve overall quality of life for fibromyalgia patients. Secondly, the market segmentation includes Therapy, comprising non-pharmacological interventions aimed at improving functional capacity, coping mechanisms, and overall well-being. Physical therapy, occupational therapy, and exercise therapy are integral components of fibromyalgia management, focusing on improving muscle strength, flexibility, and endurance, as well as addressing posture and body mechanics. Moreover, cognitive-behavioral therapy (CBT) and other psychological interventions help patients develop coping strategies, manage stress, and improve sleep hygiene, thereby reducing the impact of fibromyalgia symptoms on daily functioning and mental health. Additionally, complementary and alternative therapies, such as acupuncture, massage therapy, and mindfulness-based practices, offer holistic approaches to symptom management and pain relief for fibromyalgia patients. Lastly, the segment labeled Others encompasses emerging treatment modalities, novel interventions, and adjunctive therapies that may play a role in fibromyalgia management. This includes innovative approaches such as transcranial magnetic stimulation (TMS), biofeedback, dietary supplements, and emerging pharmacotherapies targeting novel pathways implicated in fibromyalgia pathophysiology. Moreover, patient education, lifestyle modifications, and self-management strategies are integral components of fibromyalgia care, contributing to improved treatment outcomes and long-term symptom management. By delineating the Global Fibromyalgia Market into distinct treatment categories, stakeholders can gain valuable insights into the diverse approaches and interventions available for managing this complex and multifaceted condition, ultimately enhancing patient care and quality of life for individuals affected by fibromyalgia.
Global Fibromyalgia Market, Segmentation by Route of Administration
The Global Fibromyalgia Market has been segmented by Route of Administration into Oral, Parenteral, and Others.
Oral administration represents one of the most common routes, involving the ingestion of medications such as analgesics, antidepressants, anticonvulsants, and muscle relaxants in pill, capsule, or liquid form. Oral medications offer convenience, ease of administration, and patient compliance, making them a preferred choice for long-term management of fibromyalgia symptoms. Parenteral administration, on the other hand, involves the delivery of medications via injection or infusion routes, bypassing the gastrointestinal tract and facilitating rapid absorption into the bloodstream. Parenteral medications may include intravenous (IV), intramuscular (IM), or subcutaneous (SC) injections of analgesics, corticosteroids, or biologic agents, providing more immediate and targeted relief for severe or refractory fibromyalgia symptoms. Additionally, the "Others" category encompasses alternative routes of administration, such as transdermal patches, topical creams or gels, inhalation therapies, and intranasal formulations, which offer alternative options for patients who may have difficulty swallowing pills or prefer non-oral routes of drug delivery. Transdermal patches, for example, deliver medication through the skin, providing sustained release and steady blood levels of therapeutic agents over time. Topical creams or gels containing analgesic agents such as lidocaine or capsaicin offer localized relief for muscle and joint pain, while inhalation therapies may include nebulized medications or essential oils for respiratory symptoms associated with fibromyalgia. Intranasal formulations, such as nasal sprays or powders, provide a non-invasive route of drug delivery for medications targeting central nervous system symptoms. Overall, the segmentation by Route of Administration in the Global Fibromyalgia Market reflects the diverse treatment options available to patients, allowing healthcare providers to tailor therapeutic regimens to individual patient needs, preferences, and treatment responses, ultimately improving outcomes and quality of life for individuals living with fibromyalgia.
Global Fibromyalgia Market, Segmentation by End User
The Global Fibromyalgia Market has been segmented by End User into Hospitals, Homecare, Specialty Clinics, and Others.
Hospitals represent a primary hub for managing fibromyalgia, offering comprehensive medical services, specialized diagnostic testing, and multidisciplinary treatment approaches. Within hospital settings, fibromyalgia patients may access various departments such as rheumatology, pain management, neurology, and physical therapy, where healthcare professionals collaborate to address the complex needs of individuals with fibromyalgia. Additionally, hospitals serve as referral centers for severe cases or complex presentations of fibromyalgia, providing access to advanced interventions, including inpatient care and specialized procedures. Secondly, homecare services play a vital role in supporting fibromyalgia patients in managing their symptoms and improving their quality of life within the comfort of their homes. Homecare services encompass a range of interventions, including nursing care, physical therapy, occupational therapy, and assistance with activities of daily living, tailored to meet the individual needs and preferences of fibromyalgia patients. Thirdly, specialty clinics dedicated to fibromyalgia management offer specialized expertise, resources, and comprehensive care for patients with fibromyalgia. These clinics may include fibromyalgia centers of excellence, pain management clinics, integrative medicine clinics, and multidisciplinary treatment centers, where patients receive holistic care and access to a range of treatment modalities, including pharmacological and non-pharmacological approaches. Specialty clinics often serve as hubs for research, education, and advocacy, contributing to advancements in fibromyalgia understanding and treatment. Lastly, the category of "Others" encompasses a variety of healthcare settings and providers that may play a role in fibromyalgia management, including primary care clinics, community health centers, rehabilitation facilities, and telemedicine platforms. These settings offer diverse services and resources for fibromyalgia patients, ranging from routine check-ups and medication management to counseling, support groups, and virtual consultations.
Global Fibromyalgia Market, Segmentation by Distribution Channel
The Global Fibromyalgia Market has been segmented by Distribution Channel into Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
Hospital Pharmacies serve as crucial points of care for fibromyalgia patients, offering a wide range of pharmaceutical products and specialized medications prescribed by healthcare professionals. These pharmacies provide convenient access to medications and treatments within hospital settings, ensuring prompt and efficient dispensing of prescriptions and facilitating coordinated care for patients. Online Pharmacies represent a rapidly growing distribution channel, offering the convenience of remote ordering and delivery of medications directly to patients' homes. Online pharmacies provide a convenient option for individuals with mobility limitations, those living in remote areas, or those seeking privacy and discretion in obtaining their medications. Retail Pharmacies, including chain pharmacies, independent pharmacies, and community pharmacies, play a pivotal role in extending access to fibromyalgia treatments to local communities. These pharmacies offer a wide selection of over-the-counter and prescription medications, as well as health-related products and services, providing personalized care and support to patients managing fibromyalgia symptoms. By segmenting the market based on distribution channels, the Global Fibromyalgia Market aims to optimize the delivery of treatments, enhance patient convenience, and improve overall access to care for individuals affected by this chronic condition.
Global Fibromyalgia Market, Segmentation by Geography
In this report, the Global Fibromyalgia Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Fibromyalgia Market Share (%), by Geographical Region, 2024
The global fibromyalgia market is analysed and market size insights and trends are provided by diagnosis, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global fibromyalgia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for global fibromyalgia market throughout the forecasted period due to increasing geriatric population, increasing initiatives taken by the pharmaceutical organizations to generate novel formulation specific for arthritis population.
Asia-Pacific dominates the market due to increasing initiatives by the government and pharmaceutical organizations to spread awareness and presence of generic manufacturers.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Fibromyalgia Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increased Incidence of Fibromyalgia
- Research and Development Investments
-
Rising Demand for Oral Drugs- Oral medications offer several advantages, including ease of administration, improved patient compliance, and reduced healthcare resource utilization compared to other routes of drug delivery. In the context of fibromyalgia, where chronic pain and other debilitating symptoms can significantly impact daily functioning and quality of life, oral drugs provide a convenient and effective means of symptom management. Patients often prefer oral medications due to their familiarity, perceived effectiveness, and ability to integrate seamlessly into their daily routines.
Healthcare providers also favor oral drugs for fibromyalgia management, as they offer flexibility in dosing regimens, allow for titration based on individual patient needs, and minimize the need for invasive procedures or specialized administration techniques. Furthermore, the availability of a wide range of oral medications with diverse mechanisms of action, including analgesics, antidepressants, anticonvulsants, and muscle relaxants, enables personalized treatment approaches tailored to the specific symptoms and comorbidities of fibromyalgia patients. As the demand for oral drugs continues to rise in response to patient preferences and clinical efficacy, pharmaceutical companies and healthcare providers are poised to capitalize on this trend by developing innovative formulations, expanding treatment options, and optimizing treatment algorithms to meet the evolving needs of fibromyalgia patients.
Restraints
- Lack of Specific Diagnostic Tests
- Lack of skilled professionals
-
High Cost- Fibromyalgia is a chronic condition that requires long-term management involving multiple healthcare interventions, including pharmacotherapy, psychotherapy, physical therapy, and lifestyle modifications. The cumulative expenses associated with medications, healthcare consultations, diagnostic tests, and supportive therapies can impose a considerable financial burden on patients, particularly those without adequate health insurance coverage or limited financial resources.
Additionally, the high cost of fibromyalgia treatment may lead to medication non-adherence or delays in seeking medical care, potentially exacerbating symptoms and reducing overall treatment effectiveness. Moreover, healthcare systems may face challenges in allocating resources and providing affordable access to comprehensive fibromyalgia care, particularly in regions with limited healthcare infrastructure or reimbursement limitations. Addressing the high cost of fibromyalgia management requires a multi-faceted approach, including initiatives to improve healthcare affordability, enhance insurance coverage for fibromyalgia treatments, promote cost-effective interventions, and foster collaboration between healthcare stakeholders to optimize resource utilization and mitigate financial barriers to care.
Opportunities
- Increased Clinical Research
- Personalized Medicine Approaches
-
Increasing Demand for Retail Pharmacies- Retail pharmacies serve as crucial distribution channels for prescription medications, over-the-counter treatments, and healthcare products tailored to fibromyalgia management. With the rising prevalence of fibromyalgia and the growing awareness of the condition among healthcare providers and patients, there is a corresponding increase in the demand for specialized medications and supportive therapies. Retail pharmacies play a vital role in meeting this demand by stocking a wide range of medications commonly used in fibromyalgia treatment, including analgesics, antidepressants, muscle relaxants, and anticonvulsants. Moreover, retail pharmacies offer personalized services such as medication counseling, adherence support, and medication synchronization programs, enhancing patient engagement and adherence to treatment regimens.
The expansion of retail pharmacy chains, the adoption of digital health technologies, and the integration of telepharmacy services further enhance accessibility and convenience for fibromyalgia patients, particularly those with limited mobility or living in remote areas. Additionally, retail pharmacies serve as important hubs for patient education, providing resources, information, and support networks to empower individuals with fibromyalgia to actively manage their condition and improve their quality of life. As the demand for retail pharmacy services continues to grow, there are ample opportunities for collaboration between pharmaceutical companies, healthcare providers, and retail pharmacy chains to optimize medication management, enhance patient outcomes, and address the evolving needs of fibromyalgia patients in the community.
Competitive Landscape Analysis
Key players in Global Fibromyalgia Market include:
- Pfizer Inc
- AstraZeneca
- Johnson and Johnson Services Inc
- F. Hoffmann-La Roche Ltd
- Janssen Pharmaceuticals, Inc
- Sanofi
- Merck & Co., Inc
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- Bristol Myers Squibb Company
- GlaxoSmithKline Plc
- Bayer AG
- Perrigo Company plc
- Sun Pharmaceutical Industries Ltd
- Cipher Pharmaceuticals Inc
- Novartis AG
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Diagnosis
- Market Snapshot, By Treatment
- Market Snapshot, By Route of Administration
- Market Snapshot, By End User
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Global Fibromyalgia Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Increased Incidence of Fibromyalgia
-
Research and Development Investments
-
Rising Demand for Oral Drugs
-
- Restraints
-
Lack of Specific Diagnostic Tests
-
Lack of skilled professionals
-
High Cost
-
- Opportunities
- Increased Clinical Research
- Personalized Medicine Approaches
- Increasing Demand for Retail Pharmacies
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Fibromyalgia Market, By Diagnosis, 2021 - 2031 (USD Million)
- Blood Tests
- Others
- Global Fibromyalgia Market, By Treatment, 2021 - 2031 (USD Million)
- Medication
- Therapy
- Others
-
Global Fibromyalgia Market, By Route of Administration, 2021 - 2031 (USD Million)
-
Oral
-
Parenteral
-
Others
-
-
Global Fibromyalgia Market, By End User, 2021 - 2031 (USD Million)
-
Hospitals
-
Homecare
-
Specialty Clinics
-
Others
-
- Global Fibromyalgia Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Global Fibromyalgia Market, By Geography, 2021 - 2031 (USD Million)
-
North America
-
United States
-
Canada
-
-
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Nordic
-
Benelux
-
Rest of Europe
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia & New Zealand
-
South Korea
-
ASEAN (Association of South East Asian Countries)
-
Rest of Asia Pacific
-
-
Middle East & Africa
-
GCC
-
Israel
-
South Africa
-
Rest of Middle East & Africa
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
Rest of Latin America
-
-
- Global Fibromyalgia Market, By Diagnosis, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
-
Pfizer Inc
-
AstraZeneca
-
Johnson and Johnson Services Inc
-
F. Hoffmann-La Roche Ltd
-
Janssen Pharmaceuticals, Inc
-
Sanofi
-
Merck & Co., Inc
-
Mylan N.V.
-
Teva Pharmaceutical Industries Ltd
-
Bristol Myers Squibb Company
-
GlaxoSmithKline Plc
-
Bayer AG
-
Perrigo Company plc
-
Sun Pharmaceutical Industries Ltd
-
Cipher Pharmaceuticals Inc
-
Novartis AG
-
- Company Profiles
- Analyst Views
- Future Outlook of the Market